“President Donald J. Trump Delivers On A COVID-19 Promise: Pfizer Announced COVID-19 Breakthrough


NEW YORK----late Sunday, November 9, 2020 Pfizer announced "The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program…

“Coronavirus (COVID-19) Update: Daily Roundup October 20, 2020”


WASHINGTON, D.C.---The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The FDA posted a new “FDA Insight” podcast featuring Deputy Commissioner Anand Shah, M.D., and Dr. Peter Marks, the Director of FDA's Center for Biologics Evaluation and Research, discussing the…

“Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate”


  NEW BRUNSWICK, N.J., September 23, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the…

President Trump Executive Order Request HHS To Report on Efforts to Improve Rural Healthcare To Build on 94 New Rural-Focused Projects


WASHINGTON, D.C.--President Trump signed an executive order requesting that the Department of Health and Human Services produce a report on existing and upcoming efforts to improve rural healthcare. Today, HHS released the Rural Action Plan, the first HHS-wide assessment of rural healthcare efforts in more than 18 years and the…

“Statement from the Press Secretary Regarding the Administration’s Purchase of 150 Million Rapid COVID-19 Tests”


WASHINGTON, D.C.--Today, the Trump Administration is pleased to announce the purchase and production of 150 million rapid tests to be distributed across the country.  In March, President Donald J. Trump called for the development of a low cost, reliable point-of-care test.  To deliver on this promise, the Administration has partnered…

“FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation”


WASHINGTON, D.C.---the U.S. Food and Drug Administration granted accelerated approval to Viltepso (viltolarsen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This is the second FDA-approved targeted treatment for patients with…

“FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration’s Fight Against Pandemic”


WASHINGTON, D.C.-- the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the agency’s ongoing efforts to fight COVID-19. Based on scientific evidence available, the FDA concluded, as outlined in its decision memorandum,…